Equibles does not estimate personal net worth.
Get an email with a short summary when Cadrenal Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get CVKD alertsTerry Ferguson has spoken on 2 investor events across 1 company, most recently for Cadrenal Therapeutics, Inc. on May 28, 2026. Cadrenal Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Cadrenal Therapeutics, Inc. includes John P. Sharp (CFO), Matthew K. Szot (CFO), Quang X. Pham (CFO, Chief Accounting Officer and Board Member) and 7 others.
“Hello, everyone, and thank you for continuing to join us throughout the day here at the Lithium Partners Spring 2026 Investor Conference. My name is Robert Bloom, Managing Partner here at Lithium.”
“I'm the chief medical officer at Cadrenal Therapeutics. At Cadrenal, we're focused on developing novel drugs to bridge gaps in anticoagulation. Anticoagulants are blood thinners to prevent heart attacks, strokes, and deaths for patients with a variety of cardiovascular conditions.”
Transcript header (unverified)
Biotechnology · Healthcare
